Patents by Inventor Anna N. Moraitis
Anna N. Moraitis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11084872Abstract: Breast cancer cells lacking ER protein expression, PgR protein expression and/or showing absence of HER2 protein over-expression (i.e., triple-negative breast cancer cells, basal-like) can be efficiently targeted with an anti-KAAG1 antibody and killed upon delivery of a therapeutic moiety. Antibodies and antigen binding fragments that specifically binds to KAAG1 may thus be used for the, detection and therapeutic treatment of breast cancer cells that are negative for at least one of these markers. The use of antibody conjugates in the treatment of triple-negative breast cancer and/or basal-like breast cancer is disclosed herein.Type: GrantFiled: October 18, 2018Date of Patent: August 10, 2021Assignee: ADC Therapeutics SAInventors: Gilles Bernard Tremblay, Anna N. Moraitis, Mario Filion
-
Publication number: 20210054067Abstract: Antibodies and antigen binding fragments that specifically bind to KAAG1 and which may be used in the treatment, detection and diagnosis of cancer comprising KAAG1-expressing cells are disclosed herein. Cells expressing the antibodies and antigen binding fragments as well as methods of detecting and treating cancer using the antibodies and fragments are also disclosed. Cancer indications which may benefit from such treatment or detection include ovarian cancer, renal cancer, lung cancer, colorectal cancer, breast cancer, brain cancer, and prostate cancer, as well as melanomas.Type: ApplicationFiled: December 9, 2019Publication date: February 25, 2021Inventors: Gilles Bernard Tremblay, Anna N. Moraitis, Traian Sulea, Mario Filion
-
Patent number: 10597450Abstract: Novel antibodies and antigen binding fragments that specifically bind to KAAG1 and which may be used in the treatment, detection and diagnosis of cancer comprising KAAG1-expressing cells are disclosed herein. Cells expressing the antibodies and antigen binding fragments as well as methods of detecting and treating cancer using the antibodies and fragments are also disclosed. Cancer indications which may benefit from such treatment or detection include ovarian cancer, renal cancer, lung cancer, colorectal cancer, breast cancer, brain cancer, and prostate cancer, as well as melanomas.Type: GrantFiled: November 13, 2017Date of Patent: March 24, 2020Assignee: ADC Therapeutics SAInventors: Gilles Bernard Tremblay, Anna N. Moraitis, Traian Sulea, Mario Filion
-
Publication number: 20190119366Abstract: Breast cancer cells lacking ER protein expression, PgR protein expression and/or showing absence of HER2 protein over-expression (i.e., triple-negative breast cancer cells, basal-like) can be efficiently targeted with an anti-KAAG1 antibody and killed upon delivery of a therapeutic moiety. Antibodies and antigen binding fragments that specifically binds to KAAG1 may thus be used for the, detection and therapeutic treatment of breast cancer cells that are negative for at least one of these markers. The use of antibody conjugates in the treatment of triple-negative breast cancer and/or basal-like breast cancer is disclosed herein.Type: ApplicationFiled: October 18, 2018Publication date: April 25, 2019Inventors: Gilles Bernard TREMBLAY, Anna N. MORAITIS, Mario FILION
-
Publication number: 20180291099Abstract: Novel antibodies and antigen binding fragments that specifically bind to KAAG1 and which may be used in the treatment, detection and diagnosis of cancer comprising KAAG1-expressing cells are disclosed herein. Cells expressing the antibodies and antigen binding fragments as well as methods of detecting and treating cancer using the antibodies and fragments are also disclosed. Cancer indications which may benefit from such treatment or detection include ovarian cancer, renal cancer, lung cancer, colorectal cancer, breast cancer, brain cancer, and prostate cancer, as well as melanomas.Type: ApplicationFiled: November 13, 2017Publication date: October 11, 2018Inventors: Gilles Bernard Tremblay, Anna N. Moraitis, Traian Sulea, Mario Filion
-
Patent number: 9828426Abstract: Novel antibodies and antigen binding fragments that specifically bind to KAAG1 and which may be used in the treatment, detection and diagnosis of cancer comprising KAAG1-expressing cells are disclosed herein. Cells expressing the antibodies and antigen binding fragments as well as methods of detecting and treating cancer using the antibodies and fragments are also disclosed. Cancer indications which may benefit from such treatment or detection include ovarian cancer, renal cancer, lung cancer, colorectal cancer, breast cancer, brain cancer, and prostate cancer, as well as melanomas.Type: GrantFiled: April 25, 2016Date of Patent: November 28, 2017Assignee: ADC Therapeutics SAInventors: Gilles Bernard Tremblay, Anna N. Moraitis, Traian Sulea, Mario Filion
-
Publication number: 20170174753Abstract: Breast cancer cells lacking ER protein expression, PgR protein expression and/or showing absence of HER2 protein over-expression (i.e., triple-negative breast cancer cells, basal-like) can be efficiently targeted with an anti-KAAG1 antibody and killed upon delivery of a therapeutic moiety. Antibodies and antigen binding fragments that specifically binds to KAAG1 may thus be used for the, detection and therapeutic treatment of breast cancer cells that are negative for at least one of these markers. The use of antibody conjugates in the treatment of triple-negative breast cancer and/or basal-like breast cancer is disclosed herein.Type: ApplicationFiled: January 9, 2013Publication date: June 22, 2017Applicant: Alethia Biotherapeutics Inc.Inventors: Gilles Bernard TREMBLAY, Anna N. MORAITIS, Mario FILION
-
Publication number: 20170129956Abstract: The present invention relates to the treatment of osteogenesis imperfecta with anti-Siglec-15 antibodies or antigen binding fragment thereof. Treatment of osteogenesis imperfecta type VI is particularly contemplated.Type: ApplicationFiled: June 17, 2015Publication date: May 11, 2017Applicant: Daiichi Sankyo Company, LimitedInventors: Mario FILION, Gilles Bernard TREMBLAY, Anna N. MORAITIS
-
Patent number: 9493562Abstract: Antibodies and antigen binding fragments that specifically binds to Siglec-15 are described herein. These antibodies or antigen binding fragments may have the ability of inhibiting differentiation of osteoclasts and/or the ability of inhibiting the bone resorption activity of osteoclasts. Compositions and cells expressing anti-Siglec-15 antibodies or antigen binding fragments are also disclosed herewith. Anti-Siglec-15 antibodies may also be useful for the treatment of bone loss, or bone diseases. Methods for the detection or diagnosis of bone loss or bone-related diseases are also described.Type: GrantFiled: July 17, 2013Date of Patent: November 15, 2016Assignee: Alethia Biotherapeutics Inc.Inventors: Matthew Stuible, Gilles Bernard Tremblay, Traian Sulea, Anna N. Moraitis, Mario Filion
-
Publication number: 20160304605Abstract: Novel antibodies and antigen binding fragments that specifically bind to KAAG1 and which may be used in the treatment, detection and diagnosis of cancer comprising KAAG1-expressing cells are disclosed herein. Cells expressing the antibodies and antigen binding fragments as well as methods of detecting and treating cancer using the antibodies and fragments are also disclosed. Cancer indications which may benefit from such treatment or detection include ovarian cancer, renal cancer, lung cancer, colorectal cancer, breast cancer, brain cancer, and prostate cancer, as well as melanomas.Type: ApplicationFiled: April 25, 2016Publication date: October 20, 2016Inventors: Gilles Bernard TREMBLAY, Anna N. MORAITIS, Traian SULEA, Mario FILION
-
Patent number: 9393302Abstract: Novel antibodies and antigen binding fragments that specifically bind to KAAG1 and which may be used in the treatment, detection and diagnosis of cancer comprising KAAG1-expressing cells are disclosed herein. Cells expressing the antibodies and antigen binding fragments as well as methods of detecting and treating cancer using the antibodies and fragments are also disclosed. Cancer indications which may benefit from such treatment or detection include ovarian cancer, renal cancer, lung cancer, colorectal cancer, breast cancer, brain cancer, and prostate cancer, as well as melanomas.Type: GrantFiled: December 2, 2014Date of Patent: July 19, 2016Assignee: Alethia Biotherapeutics Inc.Inventors: Gilles Bernard Tremblay, Anna N. Moraitis, Traian Sulea, Mario Filion
-
Publication number: 20150209427Abstract: Novel antibodies and antigen binding fragments that specifically bind to KAAG1 and which may be used in the treatment, detection and diagnosis of cancer comprising KAAG1-expressing cells are disclosed herein. Cells expressing the antibodies and antigen binding fragments as well as methods of detecting and treating cancer using the antibodies and fragments are also disclosed. Cancer indications which may benefit from such treatment or detection include ovarian cancer, renal cancer, lung cancer, colorectal cancer, breast cancer, brain cancer, and prostate cancer, as well as melanomas.Type: ApplicationFiled: December 2, 2014Publication date: July 30, 2015Inventors: Gilles Bernard TREMBLAY, Anna N. MORAITIS, Traian SULEA, Mario FILION
-
Publication number: 20150139982Abstract: Antibodies and antigen binding fragments that specifically binds to Siglec-15 are described herein. These antibodies or antigen binding fragments may have the ability of inhibiting differentiation of osteoclasts and/or the ability of inhibiting the bone resorption activity of osteoclasts. Compositions and cells expressing anti-Siglec-15 antibodies or antigen binding fragments are also disclosed herewith. Anti-Siglec-15 antibodies may also be useful for the treatment of bone loss, or bone diseases. Methods for the detection or diagnosis of bone loss or bone-related diseases are also described.Type: ApplicationFiled: July 17, 2013Publication date: May 21, 2015Applicant: ALETHIA BIOTHERAPEUTICS INC.Inventors: Matthew Stuible, Gilles Bernard Tremblay, Traian Sulea, Anna N. Moraitis, Mario Filion
-
Patent number: 8937163Abstract: Novel antibodies and antigen binding fragments that specifically bind to KAAG1 and which may be used in the treatment, detection and diagnosis of cancer comprising KAAG1-expressing cells are disclosed herein. Cells expressing the antibodies and antigen binding fragments as well as methods of detecting and treating cancer using the antibodies and fragments are also disclosed. Cancer indications which may benefit from such treatment or detection include ovarian cancer, renal cancer, lung cancer, colorectal cancer, breast cancer, brain cancer, and prostate cancer, as well as melanomas.Type: GrantFiled: March 28, 2012Date of Patent: January 20, 2015Assignee: Alethia Biotherapeutics Inc.Inventors: Gilles Bernard Tremblay, Anna N. Moraitis, Traian Sulea, Mario Filion
-
Publication number: 20140140990Abstract: Novel antibodies and antigen binding fragments that specifically bind to KAAG1 and which may be used in the treatment, detection and diagnosis of cancer comprising KAAG1-expressing cells are disclosed herein. Cells expressing the antibodies and antigen binding fragments as well as methods of detecting and treating cancer using the antibodies and fragments are also disclosed. Cancer indications which may benefit from such treatment or detection include ovarian cancer, renal cancer, lung cancer, colorectal cancer, breast cancer, brain cancer, and prostate cancer, as well as melanomas.Type: ApplicationFiled: March 28, 2012Publication date: May 22, 2014Applicants: National Research Council of Canada, Alethia Biotherapeutics Inc.Inventors: Gilles Bernard Tremblay, Anna N. Moraitis, Traian Sulea, Mario Filion